Having seen Acadia’s professionalism I wouldn’t have any problems with Neuren striking another deal with Acadia for some of the indications but not all of 2591.
No doubt they would want full usage in USA like trof.
I don't think they could afford 2591 exclusivity of all indications (100+) nor do I think they would have the logistical capability to cope.
A BP would have world wide resources and funds to run many trials at once
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$12.85 |
Change
-0.110(0.85%) |
Mkt cap ! $1.598B | |||
| Open | High | Low | Value | Volume |
| $12.82 | $13.05 | $12.53 | $6.559M | 511.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1657 | $12.83 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $12.85 | 6303 | 1 |
View Market Depth
| Last trade - 16.10pm 17/06/2025 (20 minute delay) ? |
| NEU (ASX) Chart |